Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1407-1413

  Roomi, M W ^a   Kalinovsky, T ^a   Rath, M ^a   Niedzwiecki, Aleksandra ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

DU 145; Matrix metalloproteinases 2; Matrix metalloproteinases 9; Nutrient mixture; PC 3; Prostate cancer; Tissue inhibitors of metalloproteinases; Urokinase plasminogen activators

Indexed keywords

ASCORBIC ACID; GELATINASE A; GELATINASE B; GREEN TEA EXTRACT; LYSINE; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROLINE; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION; ZYMOGRAPHY;

CELL LINE, TUMOR; CULTURE MEDIA; ENZYME ASSAYS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICRONUTRIENTS; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80053555335     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1434     Document Type: Article

References (48)

1. Jemal A, Seigal R, Xu J and Ward E: Cancer statistics, 2010. CA cancer J Clin 60: 277-300, 2010.
2. Fidler IJ: Molecular biology of cancer: invasion and metastasis. In: Cancer: Principles and Practice of Oncology. 5th edition. De Vita VT, Hellman S and Rosenberg SA (eds). Lippincott-Raven, Philadelphia, pp135-152, 1997.
3. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
4. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (Suppl 16): S15-S18, 2002.
5. Chambers AF and Matrisian LM: Changing views on the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997. (Pubitemid 27371946)
6. Kleiner DL and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999.
7. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
8. Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E and Guérin SL: MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 11: 1101-1111, 2005.
9. Garzetti G, Ciavattini A, Lucarini G, Goteri G, De Nicolis M, Garbisa S, Masiero L, Romanini C and Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995. (Pubitemid 26095103)
10. Gohji K, Fujomoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S and Nakijima M: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79: 96-101, 1998 (Pubitemid 28157734)
11. Lokeshwar BL: MMP inhibition in prostate cancer. Ann NY Acad Sci 878: 271-289, 1999.
12. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM and Slawin KM: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression and metastasis. J Clin Onc 25: 349-355, 2007. (Pubitemid 350002982)
13. Achbarou A, Laiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994. (Pubitemid 24138727)
14. Yurchenko PD and Schitny JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
15. Barsky SH, Siegel GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1983. (Pubitemid 13039938)
16. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980. (Pubitemid 10098769)
17. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 10: 383-392, 2001.
18. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
19. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17-25, 2002. (Pubitemid 34082839)
20. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
21. Evans CP, Elfman F, Parangi S, Conn M, Cunha G and Shuman MA: Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57: 3594-3599, 1997. (Pubitemid 27355512)
22. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L and Val de Kier Joffé E: Effects of synthetic urokinase on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40: 209-223, 1996. (Pubitemid 26336116)
23. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomol Med 7: 17-23, 1992.
24. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-543, 2010.
25. Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
26. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 19: 179-184, 2005. (Pubitemid 40450393)
27. Amin ARMR, Kucek O, Khuri FR and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27: 2712-2725, 2009.
28. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
29. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002. (Pubitemid 34455046)
30. Kemberling JK, Hampton JA, Keck RW, Gomez MA and Selman SH: Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170: 773-776, 2003. (Pubitemid 36999553)
31. Sato D and Matsushima M: Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10: 160-166, 2003. (Pubitemid 36470027)
32. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996. (Pubitemid 26249199)
33. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71: S1698-S1702, 2000.
34. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998. (Pubitemid 28376804)
35. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
36. Hara Y: Green tea: Health Benefits and Applications. Marcel Dekker, New York, Basel, 2001.
37. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
38. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999. (Pubitemid 30064181)
39. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
40. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003. (Pubitemid 36232786)
41. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: The utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982. (Pubitemid 12029882)
42. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997. (Pubitemid 27337953)
43. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493, 1998. (Pubitemid 28386538)
44. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005. (Pubitemid 41420895)
45. Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995.
46. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996. (Pubitemid 26147697)
47. Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997. (Pubitemid 27101848)
48. Roomi MW, Ivanov V, Netke SP, Niedzwiecki A and Rath M: Serum markers of the liver, heart, and kidney and lipid profile and histopathology in ODS rats treated with nutrient synergy. J Am Coll Nutr 22: abs. 86, 2003.